

# Davos@home: eHealth support of patients with severe asthma during and after AACT (Alpine Altitude Climate Therapy)

Gepubliceerd: 12-02-2021 Laatste bijgewerkt: 15-05-2024

The use of the ehealth application PatientCoach combined with home monitoring devices supports sustained long term asthma control after AACT

|                             |                          |
|-----------------------------|--------------------------|
| <b>Ethische beoordeling</b> | Niet van toepassing      |
| <b>Status</b>               | Werving nog niet gestart |
| <b>Type aandoening</b>      | -                        |
| <b>Onderzoekstype</b>       | Interventie onderzoek    |

## Samenvatting

### ID

NL-OMON27453

### Bron

NTR

### Verkorte titel

Davos@home

### Aandoening

Severe or uncontrolled asthma

## Ondersteuning

**Primaire sponsor:** Vereniging Nederland Davos, Stichting Astma Bestrijding

**Overige ondersteuning:** Vereniging Nederland Davos, Stichting Astma Bestrijding

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

## Toelichting onderzoek

### Achtergrond van het onderzoek

In uncontrolled or severe asthma, alpine altitude climate treatment (AACT) may be used as add-on therapy, according to the Dutch severe asthma guidelines. AACT at the Davos Asthma Centre Davos combines a clinical multidisciplinary treatment programme with environmental trigger avoidance in the alpine climate. The treatment includes optimisation of asthma control, interactive patient self- management education, a personalised exercise program and sessions addressing behavioural aspects of living with a chronic disease and problems such as anxiety, stress and depression. Once the patient returns to his/her home environment, there is a risk of relapse. In a previous project we showed that such a relapse in patients with severe asthma after discharge from AACT can be partially attenuated by eHealth support of self-management with a web-based application called PatientCoach. We improved PatientCoach based on feedback of patients and professionals and made it available as an application for a smartphone.

Recent advances in the use of bio-wearables and home-monitoring systems might also improve asthma outcomes and could be integrated into PatientCoach. These potential improvements must be weighed against feasibility of use, since more devices and measurements also require more time.

We plan to perform a pragmatic randomized controlled trial in which we will evaluate the clinical effectiveness of the PatientCoach app with home-monitoring devices (intervention) as compared to the PatientCoach app without home-monitoring devices (control) in patients with severe asthma after AACT with a follow-up period of 12 months.

### Doel van het onderzoek

The use of the ehealth application PatientCoach combined with home monitoring devices supports sustained long term asthma control after AACT

### Onderzoeksopzet

Baseline, 3 months, 6 months, 9 months, 12 months.

### Onderzoeksproduct en/of interventie

PatientCoach app with home monitoring devices (spirometer, activity meter, FeNO measurement device)

## Contactpersonen

### Publiek

Nederlands Astmacentrum Davos  
KB Fieten

0814178000

### Wetenschappelijk

Nederlands Astmacentrum Davos  
KB Fieten

0814178000

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Adults ( $\geq 18$  years) with uncontrolled or severe asthma, despite using high doses of inhaled corticosteroids combined with long-acting bronchodilators for more than 1 year, who are eligible for ACT. Uncontrolled asthma is defined as having two or more exacerbations per year requiring OCS and / or an ACQ of 1.5 or higher.

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Not in possession of a smartphone. Illiterate.

## Onderzoeksopzet

### Opzet

Type: Interventie onderzoek  
Onderzoeksmodel: Parallel

|             |                         |
|-------------|-------------------------|
| Toewijzing: | Gerandomiseerd          |
| Blinding:   | Open / niet geblindeerd |
| Controle:   | Geneesmiddel            |

## Deelname

|                         |                          |
|-------------------------|--------------------------|
| Nederland               |                          |
| Status:                 | Werving nog niet gestart |
| (Verwachte) startdatum: | 01-08-2021               |
| Aantal proefpersonen:   | 126                      |
| Type:                   | Verwachte startdatum     |

## Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

**Wordt de data na het onderzoek gedeeld:** Nog niet bepaald

## Ethische beoordeling

|                     |                     |
|---------------------|---------------------|
| Niet van toepassing |                     |
| Soort:              | Niet van toepassing |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 54107  
Bron: ToetsingOnline  
Titel:

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

| Register | ID             |
|----------|----------------|
| NTR-new  | NL9273         |
| CCMO     | NL75682.058.20 |
| OMON     | NL-OMON54107   |

## Resultaten